Senti Biosciences, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) for its upcoming proxy statement. This filing, known as a DEFA14A, is an amendment to the Schedule 14A information, which is required for soliciting proxy statements. The materials were filed by Senti Biosciences as the registrant, indicating that the company is preparing for actions that require shareholder votes. No filing fee was required for this submission. The filing ensures that Senti Biosciences complies with SEC regulations ahead of a shareholder meeting, although the specific resolutions or proposals to be voted on were not detailed in the announcement.

Senti Biosciences, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) for its upcoming proxy statement. This filing, known as a DEFA14A, is an amendment to the Schedule 14A information, which is required for soliciting proxy statements. The materials were filed by Senti Biosciences as the registrant, indicating that the company is preparing for actions that require shareholder votes. No filing fee was required for this submission. The filing ensures that Senti Biosciences complies with SEC regulations ahead of a shareholder meeting, although the specific resolutions or proposals to be voted on were not detailed in the announcement.